Cargando…

Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy

Myeloid-derived suppressor cells (MDSC) are a group of immature cells that produced by emergency myelopoiesis. Emerging evidences have identified the vital role of MDSC in cancer microenvironment, in which MDSC exerts both immunological and non-immunological activities to assist the progression of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Zhaonian, Li, Ruyuan, Wang, Yuanyuan, Li, Shuangying, Hong, Zhenya, Han, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543853/
https://www.ncbi.nlm.nih.gov/pubmed/34689842
http://dx.doi.org/10.1186/s40364-021-00333-5
_version_ 1784589698521366528
author Hao, Zhaonian
Li, Ruyuan
Wang, Yuanyuan
Li, Shuangying
Hong, Zhenya
Han, Zhiqiang
author_facet Hao, Zhaonian
Li, Ruyuan
Wang, Yuanyuan
Li, Shuangying
Hong, Zhenya
Han, Zhiqiang
author_sort Hao, Zhaonian
collection PubMed
description Myeloid-derived suppressor cells (MDSC) are a group of immature cells that produced by emergency myelopoiesis. Emerging evidences have identified the vital role of MDSC in cancer microenvironment, in which MDSC exerts both immunological and non-immunological activities to assist the progression of cancer. Advances in pre-clinical research have provided us the understanding of MDSC in cancer context from the perspective of molecular mechanism. In clinical scenario, MDSC and its subsets have been discovered to exist in peripheral blood and tumor site of patients from various types of cancers. In this review, we highlight the clinical value of MDSC in predicting prognosis of cancer patients and the responses of immunotherapies, therefore to propose the MDSC-inhibiting strategy in the scenario of cancer immunotherapies. Phenotypes and biological functions of MDSC in cancer microenvironment are comprehensively summarized to provide potential targets of MDSC-inhibiting strategy from the aspect of molecular mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00333-5.
format Online
Article
Text
id pubmed-8543853
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85438532021-10-25 Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy Hao, Zhaonian Li, Ruyuan Wang, Yuanyuan Li, Shuangying Hong, Zhenya Han, Zhiqiang Biomark Res Review Myeloid-derived suppressor cells (MDSC) are a group of immature cells that produced by emergency myelopoiesis. Emerging evidences have identified the vital role of MDSC in cancer microenvironment, in which MDSC exerts both immunological and non-immunological activities to assist the progression of cancer. Advances in pre-clinical research have provided us the understanding of MDSC in cancer context from the perspective of molecular mechanism. In clinical scenario, MDSC and its subsets have been discovered to exist in peripheral blood and tumor site of patients from various types of cancers. In this review, we highlight the clinical value of MDSC in predicting prognosis of cancer patients and the responses of immunotherapies, therefore to propose the MDSC-inhibiting strategy in the scenario of cancer immunotherapies. Phenotypes and biological functions of MDSC in cancer microenvironment are comprehensively summarized to provide potential targets of MDSC-inhibiting strategy from the aspect of molecular mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00333-5. BioMed Central 2021-10-24 /pmc/articles/PMC8543853/ /pubmed/34689842 http://dx.doi.org/10.1186/s40364-021-00333-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Hao, Zhaonian
Li, Ruyuan
Wang, Yuanyuan
Li, Shuangying
Hong, Zhenya
Han, Zhiqiang
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
title Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
title_full Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
title_fullStr Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
title_full_unstemmed Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
title_short Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
title_sort landscape of myeloid-derived suppressor cell in tumor immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543853/
https://www.ncbi.nlm.nih.gov/pubmed/34689842
http://dx.doi.org/10.1186/s40364-021-00333-5
work_keys_str_mv AT haozhaonian landscapeofmyeloidderivedsuppressorcellintumorimmunotherapy
AT liruyuan landscapeofmyeloidderivedsuppressorcellintumorimmunotherapy
AT wangyuanyuan landscapeofmyeloidderivedsuppressorcellintumorimmunotherapy
AT lishuangying landscapeofmyeloidderivedsuppressorcellintumorimmunotherapy
AT hongzhenya landscapeofmyeloidderivedsuppressorcellintumorimmunotherapy
AT hanzhiqiang landscapeofmyeloidderivedsuppressorcellintumorimmunotherapy